Replacing beef with cellular protein halves deforestation
Replacing 20% of global beef consumption with fermentation-derived microbial protein by 2050 could halve annual deforestation and associated carbon dioxide emissions.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Commission to establish EU health data space
/in News/by Thomas GabrielczykDigital medicine holds great opportunities. The EU Commission is therefore presenting a draft law this week that defines rules for a European Health Data Space.
Four new autoantigens trigger multiple sclerosis
/in News/by Thomas GabrielczykSwiss and Swedish researchers have uncovered four previously unkown autoantigens that trigger multiple sclerosis in mice.
TWB partners with Processium and Syngulon
/in News/by Thomas GabrielczykIndustrial biotech project managment specialist Toulouse White Biotech (TWB) has joined forces with process developer Processium and industrial synbio start-up Syngulon.
Meat consumption must fall by at least 75 percent
/in News/by Thomas GabrielczykIf our planet is to continue feeding us in the future, rich countries must significantly reduce their meat consumption by at least 75% suggests a new study by German researchers.
Vigeneron updates gene therapy collab with Daiichi Sankyo
/in News/by Thomas GabrielczykViGeneron and Daiichi Sankyo have agreed a follow-on collaboration to evaluate vgAAVs as vectors for Daiichi Sankyo novel treatment of prevalent eye diseases.
Single-use market to reach $20.8bn by 2026
/in News/by Thomas GabrielczykAnalysts from Markets & Markets today released the report "Single use Bioprocessing Market by Product.
Study shows advantages of cellular agriculture
/in News/by Thomas GabrielczykNovel foods derived from cell culture instead of animals reduce the environmental impact of diets, water and land use by 80%, report Finnish researchers.
EMA delays Valneva vaccine approval
/in News/by Thomas GabrielczykThe approval of Valneva’s Corona vaccine is delaying. The European Medicines Agencys CHMP requested additional data.
Mimetas BV participating in 325m cancer funding
/in News/by Thomas GabrielczykOrgan-on-chip disease model specialist Mimentas BV participates in a 325m funding to accelerate preclinical cancer R&D in the Netherlands.